RU2679495C2 - Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака - Google Patents

Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака Download PDF

Info

Publication number
RU2679495C2
RU2679495C2 RU2013115739A RU2013115739A RU2679495C2 RU 2679495 C2 RU2679495 C2 RU 2679495C2 RU 2013115739 A RU2013115739 A RU 2013115739A RU 2013115739 A RU2013115739 A RU 2013115739A RU 2679495 C2 RU2679495 C2 RU 2679495C2
Authority
RU
Russia
Prior art keywords
sdf
nucleic acid
seq
binding
nucleotides
Prior art date
Application number
RU2013115739A
Other languages
English (en)
Russian (ru)
Other versions
RU2013115739A (ru
Inventor
Вернер ПУРШКЕ
Флориан Ярош
Дирк Ойлберг
Свен Клуссманн
Клаус Бухнер
Кристиан Мааш
Николь Динзе
Дирк ЦБОРАЛЬСКИ
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2013115739A publication Critical patent/RU2013115739A/ru
Application granted granted Critical
Publication of RU2679495C2 publication Critical patent/RU2679495C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013115739A 2010-09-09 2011-09-09 Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака RU2679495C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009397.0 2010-09-09
EP10009397 2010-09-09
PCT/EP2011/004554 WO2012031773A1 (en) 2010-09-09 2011-09-09 Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
RU2013115739A RU2013115739A (ru) 2014-10-20
RU2679495C2 true RU2679495C2 (ru) 2019-02-11

Family

ID=44653255

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013115739A RU2679495C2 (ru) 2010-09-09 2011-09-09 Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака

Country Status (14)

Country Link
US (3) US20130310442A1 (enExample)
EP (1) EP2613789B1 (enExample)
JP (1) JP6243736B2 (enExample)
KR (1) KR101937939B1 (enExample)
CN (1) CN103108641B (enExample)
AU (1) AU2011300818B2 (enExample)
BR (1) BR112013005664B8 (enExample)
CA (1) CA2810950C (enExample)
DK (1) DK2613789T3 (enExample)
ES (1) ES2678497T3 (enExample)
MX (1) MX357770B (enExample)
RU (1) RU2679495C2 (enExample)
SG (2) SG10201506725QA (enExample)
WO (1) WO2012031773A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
WO2017178119A1 (en) * 2016-04-15 2017-10-19 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050461A1 (en) * 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
RU2270685C2 (ru) * 2000-06-26 2006-02-27 Веллстат Байолоджикс Корпорейшн Удаление клеток с использованием вирусов
WO2006126209A1 (en) * 2005-05-26 2006-11-30 Rappaport Family Institute For Research In The Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
WO2007022523A2 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2008009437A2 (en) * 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
WO2008018641A1 (en) * 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2009019007A2 (en) * 2007-08-06 2009-02-12 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof
US20090156533A1 (en) * 2001-05-18 2009-06-18 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ATE333896T1 (de) 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
EP1717583A3 (en) 2001-06-07 2007-10-10 ChemoCentryx Inc Cell migration assay
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
WO1999050461A1 (en) * 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
RU2270685C2 (ru) * 2000-06-26 2006-02-27 Веллстат Байолоджикс Корпорейшн Удаление клеток с использованием вирусов
US20090156533A1 (en) * 2001-05-18 2009-06-18 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
WO2006126209A1 (en) * 2005-05-26 2006-11-30 Rappaport Family Institute For Research In The Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
WO2007022523A2 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2008009437A2 (en) * 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
WO2008018641A1 (en) * 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2009019007A2 (en) * 2007-08-06 2009-02-12 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof

Also Published As

Publication number Publication date
EP2613789B1 (en) 2018-04-18
JP6243736B2 (ja) 2017-12-06
SG10201506725QA (en) 2015-10-29
US10093934B2 (en) 2018-10-09
CA2810950A1 (en) 2012-03-15
US9387221B2 (en) 2016-07-12
MX357770B (es) 2018-07-24
EP2613789A1 (en) 2013-07-17
HK1184699A1 (zh) 2014-01-30
US20160355821A1 (en) 2016-12-08
CN103108641A (zh) 2013-05-15
CN103108641B (zh) 2016-01-13
KR20130114094A (ko) 2013-10-16
US20160095875A1 (en) 2016-04-07
BR112013005664B8 (pt) 2023-04-25
JP2013540725A (ja) 2013-11-07
KR101937939B1 (ko) 2019-01-11
ES2678497T3 (es) 2018-08-13
AU2011300818B2 (en) 2015-11-12
US20130310442A1 (en) 2013-11-21
SG188220A1 (en) 2013-04-30
WO2012031773A1 (en) 2012-03-15
AU2011300818A1 (en) 2013-03-07
MX2013002722A (es) 2013-06-28
BR112013005664A2 (pt) 2020-08-04
DK2613789T3 (en) 2018-07-23
BR112013005664B1 (pt) 2021-11-03
CA2810950C (en) 2023-02-14
RU2013115739A (ru) 2014-10-20

Similar Documents

Publication Publication Date Title
KR101589442B1 (ko) 에스디에프-1 결합형 핵산 및 이의 용도
ES2663404T3 (es) Ácidos nucleicos de unión a SDF-1
RU2679495C2 (ru) Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака
US20230146246A1 (en) Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors
HK1184699B (en) Sdf-1 binding nucleic acids and the use thereof in cancer treatment
WO2021006305A1 (ja) ＴＧＦ－β１に対するアプタマー及びその使用